FAST FIVE: 'It Will Never Be Licensed In The US' – Analyst Warns AstraZeneca Vaccine Efficacy "Embellished"

Published by on

SVB Leerink analyst George Porges said Monday that the company is likely to be roundly criticized for its disclosure, since the safety disclosure simply stated that “no serious safety events related to the vaccine have been confirmed”, as well as for its results, which the company “tried to embellish” by highlighting a reported 90% efficacy in the relatively small sub-set of subjects in the study who received the modified initial vaccination followed by the “full dose” four weeks later.

– Bob (@wugubob) November 23, 2020 Porges believes that this product will never be licensed in the US due to the design of the company's trials and the occurrence of severe safety events that resulted in the extended clinical hold on enrollment in the US.

The findings, according to Porges, confound his original thesis that “all spike protein vaccines are created equal”, which is manifestly not the case now.

https://t.co/GqhjKIX9vl- Meg Tirrell (@megtirrell) November 23, 2020 A few weeks ago, Porges offered some positive commentary about the Pfizer vaccine and the Moderna vaccine.

Regarding the latter, he said, the successful mRNA vaccine could help burnish Moderna's reputation and transform it into a major player in the biotech space.

Categories: ZH